79-6 (CID5721353) - 98%, high purity , CAS No.301356-95-6

  • ≥98%
Item Number
C413954
Grouped product items
SKUSizeAvailabilityPrice Qty
C413954-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$97.90
C413954-10mg
10mg
In stock
$162.90
C413954-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$314.90
C413954-50mg
50mg
In stock
$532.90
C413954-100mg
100mg
In stock
$913.90

Bcl-6 Inhibitors

Basic Description

SynonymsBCL6 inhibitor;butanedioic acid
Specifications & Purity≥98%
Biochemical and Physiological Mechanisms79-6 (CID5721353) (BCL6 inhibitor) is a BCL6 inhibitor with Kd value of 138 μM.
Storage TempStore at -20°C
Shipped InIce chest + Ice pads
Product Description

Information

79-6 (CID5721353) 79-6 (CID5721353) (BCL6 inhibitor) is a BCL6 inhibitor with Kd value of 138 μM.


Targets

Bcl-6 138 μM(Kd)


In vitro

Small molecular BCL6 inhibitor 79-6 is a cell-permeable oxindole compound that selectively inhibits the transcriptional repression activity of BCL6 but does not affect BCL6 protein levels. 79-6 binds an aromatic pocket situated in the BTB domain lateral groove, induces disruption of BCL6 transcriptional complexes, reactivation of BCL6 target genes and selective killing of BCL6-dependent DLBCL cells. BCL6 can also interact with MTA3 through its RD2 domain and represses the terminal differentiation. It recruits CtBP through its DBD domain and represses its own expression. 79-6 suppresses invasive ability and colony-forming ability in both of MCF-7 and MDA231 cells. The inhibition of BCL6 with 79-6 enhanced the mRNA expression of E-cadherin in both of MCF-7 and MDA231 cells. 79-6 reverses the functions of BCL6 in the positive regulation of EMT, invasion and transcriptional repression of E-cadherin in breast cancer cells.


In vivo

Administration of 50 mg/kg/day 79-6 to SCID mice induced a 65-70% reduction in the size of established BCL6-dependent DLBCL xenografts, but had no effect on BCL6-independent DLBCLs. Therapeutic targeting of BCL6 with the small molecule 79-6 is an effective antilymphoma strategy in vivo.


Cell Research(from reference)

Cell lines:MCF-7 and MDA231 cells 

Concentrations:200 μM 

Incubation Time:48 h 

Product Properties

ALogP2.057
HBD Count1
Rotatable Bond4

Associated Targets(Human)

BCL6 Tchem B-cell lymphoma 6 protein (838 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
BCL6 Tchem BCoR-BCL6 (22 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Names and Identifiers

IUPAC Name 2-[5-(5-bromo-2-oxoindol-3-yl)-4-hydroxy-2-sulfanylidene-1,3-thiazol-3-yl]butanedioic acid
INCHI InChI=1S/C15H9BrN2O6S2/c16-5-1-2-7-6(3-5)10(12(21)17-7)11-13(22)18(15(25)26-11)8(14(23)24)4-9(19)20/h1-3,8,22H,4H2,(H,19,20)(H,23,24)
InChi Key UMZWNADQRDCKII-UHFFFAOYSA-N
Canonical SMILES C1=CC2=NC(=O)C(=C2C=C1Br)C3=C(N(C(=S)S3)C(CC(=O)O)C(=O)O)O
Isomeric SMILES C1=CC2=NC(=O)C(=C2C=C1Br)C3=C(N(C(=S)S3)C(CC(=O)O)C(=O)O)O
PubChem CID 3800971
Molecular Weight 457.28

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

3 results found

Lot NumberCertificate TypeDateItem
H2206543Certificate of AnalysisJun 17, 2022 C413954
H2206549Certificate of AnalysisJun 17, 2022 C413954
H2206550Certificate of AnalysisJun 17, 2022 C413954

Chemical and Physical Properties

SolubilitySolubility (25°C) In vitro DMSO: 91 mg/mL (199.0 mM); Water: Insoluble; Ethanol: Insoluble;
DMSO(mg / mL) Max Solubility91
DMSO(mM) Max Solubility199.002799160252
Water(mg / mL) Max Solubility<1

Related Documents

Solution Calculators